Publications by authors named "Jaime D Blais"

Claim this Profile
P
Plasma copeptin levels predict disease progression and tolvaptan efficacy in autosomal dominant polycystic kidney disease.
Ron T Gansevoort, Maatje D A van Gastel, Arlene B Chapman, Jaime D Blais, Frank S Czerwiec

Kidney Int· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Standardizing total kidney volume measurements for clinical trials of autosomal dominant polycystic kidney disease.
Marie E Edwards, Jaime D Blais, Frank S Czerwiec, Bradley J Erickson, Vicente E Torres

Clin Kidney J· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can we further enrich autosomal dominant polycystic kidney disease clinical trials for rapidly progressive patients? Application of the PROPKD score in the TEMPO trial.
Emilie Cornec-Le Gall, Jaime D Blais, Maria V Irazabal, Olivier Devuyst, Ron T Gansevoort

Nephrol Dial Transplant· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Ronald D Perrone, Jaime D Blais

Nephrol Dial Transplant· March 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rationale and Design of a Clinical Trial Investigating Tolvaptan Safety and Efficacy in Autosomal Dominant Polycystic Kidney Disease.
Vicente E Torres, Olivier Devuyst, Arlene B Chapman, Ron T Gansevoort, Ronald D Perrone, Jaime D Blais

Am J Nephrol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Ronald D Perrone, Jaime D Blais

N Engl J Med· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolerability of Aquaretic-Related Symptoms Following Tolvaptan for Autosomal Dominant Polycystic Kidney Disease: Results From TEMPO 3:4.
Olivier Devuyst, Arlene B Chapman, Susan E Shoaf, Frank S Czerwiec, Jaime D Blais

Kidney Int Rep· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevalence of autosomal dominant polycystic kidney disease in the European Union.
Cynthia J Willey, Jaime D Blais, Anthony K Hall, Holly B Krasa, Andrew J Makin

Nephrol Dial Transplant· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Performance of an Artificial Multi-observer Deep Neural Network for Fully Automated Segmentation of Polycystic Kidneys.
Timothy L Kline, Panagiotis Korfiatis, Marie E Edwards, Jaime D Blais, Frank S Czerwiec

J Digit Imaging· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial.
Vicente E Torres, Arlene B Chapman, Olivier Devuyst, Ron T Gansevoort, Ronald D Perrone, Jaime D Blais

Nephrol Dial Transplant· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Urine Osmolality, Response to Tolvaptan, and Outcome in Autosomal Dominant Polycystic Kidney Disease: Results from the TEMPO 3:4 Trial.
Olivier Devuyst, Arlene B Chapman, Ron T Gansevoort, Eiji Higashihara, Ronald D Perrone, Jaime D Blais

J Am Soc Nephrol· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan use in cancer patients with hyponatremia due to the syndrome of inappropriate antidiuretic hormone: a post hoc analysis of the SALT-1 and SALT-2 trials.
Richard J Gralla, Fatima Ahmad, Jaime D Blais, Joseph Chiodo, Wen Zhou

Cancer Med· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tolvaptan and Kidney Pain in Patients With Autosomal Dominant Polycystic Kidney Disease: Secondary Analysis From a Randomized Controlled Trial.
Niek F Casteleijn, Jaime D Blais, Arlene B Chapman, Frank S Czerwiec, Olivier Devuyst

Am J Kidney Dis· February 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic Enrichment Design in Clinical Trials for Autosomal Dominant Polycystic Kidney Disease: The TEMPO 3:4 Clinical Trial.
Maria V Irazabal, Jaime D Blais, Ronald D Perrone, Ron T Gansevoort, Arlene B Chapman

Kidney Int Rep· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.
Vicente E Torres, Eiji Higashihara, Olivier Devuyst, Arlene B Chapman, Ronald T Gansevoort, Jaime D Blais

Clin J Am Soc Nephrol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database.
Paul B Watkins, James H Lewis, Neil Kaplowitz, David H Alpers, Jaime D Blais

Drug Saf· November 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A small molecule inhibitor of endoplasmic reticulum oxidation 1 (ERO1) with selectively reversible thiol reactivity.
Jaime D Blais, King-Tung Chin, Ester Zito, Yuhong Zhang, Nimrod Heldman

J Biol Chem· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Perk-dependent translational regulation promotes tumor cell adaptation and angiogenesis in response to hypoxic stress.
Jaime D Blais, Christina L Addison, Robert Edge, Theresa Falls, Huijun Zhao

Mol Cell Biol· December 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Internal ribosome entry site-mediated translation of Apaf-1, but not XIAP, is regulated during UV-induced cell death.
Nicoleta Hosszu Ungureanu, Mireille Cloutier, Stephen M Lewis, Naomi de Silva, Jaime D Blais

J Biol Chem· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Internal translation initiation mediated by the angiogenic factor Tie2.
Eun-Hee Park, Joseph M Lee, Jaime D Blais, John C Bell, Jerry Pelletier

J Biol Chem· June 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to vesicular stomatitis virus infection requires a functional cross talk between the eukaryotic translation initiation factor 2alpha kinases PERK and PKR.
Dionissios Baltzis, Li-Ke Qu, Stavroula Papadopoulou, Jaime D Blais, John C Bell

J Virol· December 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activating transcription factor 4 is translationally regulated by hypoxic stress.
Jaime D Blais, Vasilisa Filipenko, Meixia Bi, Heather P Harding, David Ron

Mol Cell Biol· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis